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Objective. Data on the role of tobacco exposure in
systemic sclerosis (SSc; scleroderma) severity and progres-
sion are scarce. We aimed to assess the effects of smoking
on the evolution of pulmonary and skin manifestations,
based on the European Scleroderma Trials and Research
group database.
Methods. Adult SSc patients with data on smoking
history and a 12–24-month follow-up visit were included.
Associations of severity and progression of organ involve-
ment with smoking history and the Comprehensive
Smoking Index were assessed using multivariable regres-
sion analyses.
Results. A total of 3,319 patients were included
(mean age 57 years, 85% female); 66% were never smok-
ers, 23% were ex-smokers, and 11% were current smokers.
Current smokers had a lower percentage of antitopoiso-
merase autoantibodies than previous or never smokers
(31% versus 40% and 45%, respectively). Never smokers
had a higher baseline forced expiratory volume in 1 sec-
ond/forced vital capacity (FEV1/FVC) ratio than previous
and current smokers (P < 0.001). The FEV1/FVC ratio
declined faster in current smokers than in never smokers
(P = 0.05) or ex-smokers (P = 0.01). The baseline modified
Rodnan skin thickness score (MRSS) and the MRSS
decline were comparable across smoking groups. Although
heavy smoking (>25 pack-years) increased the odds of dig-
ital ulcers by almost 50%, there was no robust adverse
association of smoking with digital ulcer development.
Conclusion. The known adverse effect of smoking
on bronchial airways and alveoli is also observed in SSc
patients; however, robust adverse effects of smoking on
the progression of SSc-specific pulmonary or cutaneous
manifestations were not observed.
Systemic sclerosis (SSc; scleroderma) is a rare, mul-
tisystem autoimmune disorder (1). Hypoxia and oxidative
stress have been implicated in the pathophysiology of its
generalized microangiopathy and fibrosis (1). Although
smoking does not appear to confer a risk for SSc develop-
ment (2), it has vasoconstrictive effects and increases free-
radical exposure, and together with other proinflammatory
and immunomodulatory effects may exacerbate SSc mani-
festations (3). Data on the role of tobacco exposure with
regard to the severity of SSc organ manifestations and pro-
gression are, however, scarce, and at times contradictory
(4). A Canadian cohort study of 606 patients, for example,
demonstrated an increased frequency of digital ulcers
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(DUs) in smokers (4), whereas a study of 172 Australian
patients showed no association of smoking history with
vascular characteristics (5).
Larger studies and robust data assessing the possi-
ble effect of smoking on SSc presentation and, impor-
tantly, SSc progression are lacking. We therefore assessed
the association of tobacco exposure with the prevalence
and evolution of SSc organ manifestations.
PATIENTS AND METHODS
This study was performed using data from the multina-
tional, longitudinal European Scleroderma Trials and Research
(EUSTAR) database (6) (see Appendix A for a list of the
EUSTAR coauthors). Each center obtained local ethics committee
approval, and each patient provided written informed consent.
Data collection started in 2004. The smoking module, however,
was introduced to the database in 2013; therefore, smoking data
were only collected from that date onward. Data for this study
were exported in May 2017.
Patients were included if they were older than age 18
years, fulfilled the 1980 American College of Rheumatology
(ACR) or the 2013 ACR/European League Against Rheumatism
criteria for SSc (7,8), and if their smoking status was known.
Additionally, patients were required to have a follow-up visit 12–
24 months after baseline. Information about the core data col-
lected in the EUSTAR database can be found elsewhere (6). The
EUSTAR database smoking module collects patient-reported
smoking status (never/previous/current smoker), the number of
pack-years, and the smoking start and cessation dates.
We assessed the influence of smoking behavior on several
disease parameters: forced expiratory volume in 1 second/forced
vital capacity ratio (FEV1/FVC), FVC, single-breath diffusing
capacity for monoxide (DLCO), systolic pulmonary arterial pres-
sure (PAP) as estimated by echocardiography, modified Rodnan
skin thickness score (MRSS) (9), and DUs. Further information
about outcome measures, as well as variables describing the study
population, can be found in Supplementary Table 1 (available on
the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40557/abstract). Outcome progression was
downscaled to “rate of change per 12 months,” unless otherwise
stated.
Statistical analysis. Frequencies/percentages or means
 SDs were calculated; groups were compared using chi-square
test/Fisher’s exact test or t-test/analysis of variance. Multiple lin-
ear and logistic regression analyses were applied to adjust out-
come/exposure associations with a priori–defined potential
confounding factors (age, sex, time since the onset of Raynaud’s
phenomenon [RP], time since the first non-RP manifestation,
antibody status, and skin involvement). As the SSc-specific anti-
bodies might be on the causal pathway between smoking and
SSc organ involvement, we additionally analyzed the data with-
out adjustment for antibody status. These results can be found
in Supplementary Tables 2–4 (available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40557/abstract).
Three smoking metrics were modeled separately: model 1:
never/previous/current smoking; model 2: smoking intensity (pack-
years, where never smokers = 0 pack-years, light smokers = 0–10
pack-years, medium smokers = 10–25 pack-years, and heavy smok-
ers = >25 pack-years); and model 3: Comprehensive Smoking
Index (CSI). The CSI is an index incorporating smoking duration,
time since cessation, and smoking intensity into a single variable
(10,11). The CSI depends on 2 parameters that are estimated for
each outcome separately: the half-life (i.e., the rate at which the
smoking’s impact decays over time) and the lag-time (i.e., the delay
between smoking and its impact). Never smokers have a CSI score
of 0, and higher CSI values indicate more smoking. The CSI values
are estimated separately for each outcome variable; therefore, the
CSIs, including their ranges, are different for each outcome vari-
able. The results from the CSI regression analyses should be inter-
preted in the following way: the beta values represent the additive
increase or decrease in the outcome variable per unit increase in
the CSI. The odds ratio (OR) values represent the increase in odds
for the presence of the outcome variable per unit CSI increase.
OR values greater than 1 indicate that increased smoking increases
the likelihood of occurrence of the outcome.
Missing data were imputed using multiple imputation
with chained equations (12). The regression analyses shown in
this report are all based on imputed data; the results based on a
complete case analysis are represented in Supplementary Table 5
(available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40557/abstract). Analyses
were performed with Stata/IC15.1.
RESULTS
Patient and smoking characteristics. Of the 12,912
adult SSc patients within the EUSTAR database, 6,179
patients (48%) had no smoking data available, and a total
of 3,414 patients (26%) had no follow-up visit in the
required time frame. Therefore, 3,319 patients (26%) ful-
filled the inclusion criteria (see Supplementary Figure 1,
available at http://onlinelibrary.wiley.com/doi/10.1002/art.
40557/abstract). The demographic and disease characteris-
tics of the included and excluded patients were clinically
similar (see Supplementary Table 6, available at http://
onlinelibrary.wiley.com/doi/10.1002/art.40557/abstract).
Follow-up visits occurred a mean  SD of 1.4  0.33
years after baseline. The mean age of the patients was
57 years, and 85% were female. Demographic and
disease characteristics are shown in Table 1.
A total of 66% of the patients were never smokers,
23% were ex-smokers, and 11% were current smokers;
13% of the current smokers (1.5% of patients) stopped
smoking during the observation time, an average of 9
months after the baseline visit. The ex-smokers had smoked
a mean  SD of 18  21 pack-years during a period of 19
 12 years and ceased smoking 15  13 years previously. A
total of 49% of the ex-smokers had ceased smoking before
RP onset, and 58% had quit before the onset of the first
non-RP manifestation. The current smokers had smoked
a mean  SD of 27  30 pack-years during a period of
30 13 years.
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As patients with interstitial lung disease (ILD)
might be more likely to cease smoking than patients with-
out ILD, there might be a higher percentage of ILD
patients in the previous smoker group, which could possi-
bly lead to worse trajectories in lung function measures.
Therefore, in addition to analyzing the entire study popu-
lation, we analyzed the progression of lung function mea-
sures separately for patients with ILD on high-
resolution computed tomography (HRCT) and patients
without ILD on HRCT. Among all patients, 49% had
signs of ILD on HRCT. The smoking behavior patterns
were similar in patients with ILD and in patients without
ILD; 68% of patients in both groups were never smokers,
23% of patients with and 20% of patients without ILD
were previous smokers, and 9% of patients with and 12%
of patients without ILD were current smokers (P = 0.06).
FEV1/FVC ratio. Never smokers had a significantly
higher baseline FEV1/FVC ratio than previous and current
smokers (Table 1). These differences in baseline FEV1/
FVC ratio were seen in all 3 smoking models (Figure 1,
Table 2, and Supplementary Table 7, available at http://
onlinelibrary.wiley.com/doi/10.1002/art.40557/abstract). As
Table 1. Baseline demographic and disease characteristics of the patients, and outcome measures by smoking status*
Characteristic No.†
Never smokers
(n = 2,205)
Ex-smokers
(n = 752)
Current smokers
(n = 362) P
Age, years 3,319 57.5  14.1 57.2  12.1 52.5  11.2 <0.001
Male sex, % 3,319 8 27 29 <0.001
Disease characteristics
Time since RP onset, years 3,286 14.9  11.7 13.4  11.3 13.3  11.8 0.001
Time since first non-RP manifestation, years 2,988 11.7  8.8 10.5  8.7 8.9  7.8 <0.001
Skin involvement, % <0.001
Sine 3,106 7 8 15
Limited 64 62 58
Diffuse 29 30 27
MRSS 2,949 7.7  7.4 7.8  7.9 6.9  7.3 0.14
Follow-up MRSS 2,839 7.4  7.2 7.2  7.1 6.9  6.9 0.40
Change in MRSS 2,684 0.3  3.4 0.6  4.0 0.2  3.3 0.12
Esophageal symptoms, % 3,275 60 66 58 0.010
Stomach symptoms, % 3,241 23 23 21 0.68
Intestinal symptoms, % 3,250 27 30 29 0.24
Dyspnea NYHA functional class, % 33 34 31 0.001
I 3,114 57 54 63
II 33 34 31
III 9 10 5
IV 1 2 1
Digital ulcers, current, % 3,125 14 14 16 0.7
Digital ulcers, ever, % 3,125 46 48 45 0.56
% LVEF 2,448 62.3  6.1 61.7  6.3 63.0  5.8 0.015
FEV1/FVC ratio 2,256 97.5  13.5 95.4  15.2 92.8  15.0 <0.001
Follow-up FEV1/FVC ratio‡ 1,988 97.1  12.0 95.4  14.5 90.5  12.7 <0.001
Change in FEV1/FVC ratio§ 1,656 0.3  10.1 0.4  9.4 1.6  7.7 0.065
FVC, % of predicted 2,720 96.1  22.0 96.7  21.3 98.3  19.7 0.25
Follow-up FVC, % of predicted‡ 2,435 95.5  22.8 96.3  22.5 99.3  18.8 0.037
Change in FVC, % of predicted§ 2,166 0.6  8.5 0.4  7.7 0.1  9.4 0.45
Single-breath DLCO, % of predicted 2,583 69.8  19.6 66.4  20.4 67.1  17.8 <0.001
Single-breath follow-up DLCO, % of predicted‡ 2,253 67.5  20.0 65.6  20.0 64.4  18.1 0.021
Single-breath change in DLCO, % of predicted§ 1,977 2.0  9.1 1.7  9.2 2.0  7.8 0.86
Systolic PAP, mm Hg 2,317 28.8  16.9 26.0  1.0 24.3  12.5 <0.001
Follow-up systolic PAP, mm Hg‡ 2,055 29.2  13.6 28.5  14.1 24.7  11.6 <0.001
Change in systolic PAP, mm Hg§ 1,706 0.6  10.5 1.6  8.5 0.2  8.1 0.18
Laboratory parameters, % <0.001
ACA positive 2,508 47 47 61
Scl-70 positive 45 40 31
RNAP-III positive 3 6 6
ESR, mm/hour 2,795 22.8  18.4 18.9  16.7 18.0  14.5 <0.001
* Except where indicated otherwise, values are the mean  SD. RP = Raynaud’s phenomenon; MRSS = modified Rodnan skin thickness score;
NYHA = New York Heart Association; LVEF = left ventricular ejection fraction; FEV1/FVC = forced expiratory volume in 1 second/forced vital
capacity; DLCO = diffusing capacity for carbon monoxide; PAP = pulmonary artery pressure as estimated by echocardiography; ACA = anticentromere
antibody; RNAP III = RNA polymerase III; ESR = erythrocyte sedimentation rate.
† Number of patients with available information for each variable.
‡ Based on the follow-up visit, not the 12 months’ projection.
§ The changes in outcomes are shown downscaled to “per 12 month.”
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can be seen in Table 2, patients had a 2.7-unit lower FEV1/
FVC ratio per unit increase in the CSI. Medium and heavy
smokers had lower baseline FEV1/FVC ratios than never
smokers and light smokers (all P < 0.001) (see Supplemen-
tary Table 7, available at http://onlinelibrary.wiley.com/
doi/10.1002/art.40557/abstract). In univariable analysis, the
FEV1/FVC ratio declined similarly across smoking groups
(P = 0.065); however, in multivariable analysis, the FEV1/
FVC ratio declined faster in current smokers (Figure 1).
This result was also observed when stratifying the study pop-
ulation into ILD and non-ILD patients (data not shown).
FVC. There was no significant difference in baseline
FVC or in the FVC change between the 3 smoking groups
(Table 1). This lack of a robust effect of smoking on the
baseline FVC and on the FVC change was also observed in
all 3 multivariable models (see Figure 1, Table 2, and Sup-
plementary Table 7, available at http://onlinelibrary.wiley.
com/doi/10.1002/art.40557/abstract). This lack was also ob-
served when assessing the FVC changes separately for ILD
and non-ILD patients (data not shown).
Single-breath DLco. Smokers had lower baseline
single-breath DLCO levels than never smokers (P <
0.001) (Table 1), and smoking was associated with low
baseline single-breath DLCO in all 3 models. Single-
breath DLCO declined similarly across all 3 smoking
behavior groups in univariable analysis (Table 1) and
multivariable analysis (see Figure 1, Table 2, and Sup-
plementary Table 7, available at http://onlinelibrary.
wiley.com/doi/10.1002/art.40557/abstract). These results
were also seen when ILD and non-ILD patients were
assessed separately (data not shown).
Systolic PAP. The average baseline systolic PAP was
slightly higher in never smokers than in current or ex-smok-
ers (Table 1). These differences stayed apparent, but to a
lesser extent, not only in multivariable assessment of the
smoking groups, but also when evaluating smoking intensity
and the CSI. The systolic PAP increased similarly in the
groups in univariable analysis (Table 1) and multivariable
analysis (see Figure 1, Table 2, and Supplementary Table 7,
available at http://onlinelibrary.wiley.com/doi/10.1002/art.40557/
abstract).
Skin involvement. Regardless of the smoking matri-
ces used, no association was evident between the severity
of skin fibrosis and the smoking history. SSc sine sclero-
derma, however, was twice as prevalent in current as in ex-
or never smokers (Table 1). In all smoking models, no
clinically significant difference in MRSS evolution was
observed (see Figure 1, Tables 1 and 2, and Supplementary
Table 7, available at http://onlinelibrary.wiley.com/doi/10.
1002/art.40557/abstract).
Figure 1. Regression analysis comparing outcomes by smoking status adjusted for age, sex, time since the onset of Raynaud’s phenomenon (RP), time
since the first non-RP manifestation, antibody status, and extent of skin involvement. A, Multiple-adjusted baseline levels of the outcome measures
and corresponding 95% confidence intervals (95% CIs). B, Multiple-adjusted change rates and corresponding 95% CIs in the outcome measures
between baseline and the projected 12-month follow-up. Symbols represent never smokers (light gray), ex-smokers (dark gray), and current smokers
(black). FEV1/FVC = forced expiratory volume in 1 second/forced vital capacity; DLCO/sb = single-breath diffusing capacity for carbon monoxide;
PAPsys = systolic pulmonary artery pressure as estimated by echocardiography (mm Hg); MRSS = modified Rodnan skin thickness score.
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DUs. The prevalence of DUs was comparable in the
smoking behavior groups (Table 1). However, heavy smok-
ers had a greater likelihood of DUs than never smokers in
multivariable analysis (OR 1.6, P = 0.02) (see Supplemen-
tary Table 7, available at http://onlinelibrary.wiley.com/doi/
10.1002/art.40557/abstract). Also, a higher CSI was associ-
ated with the presence of DUs at baseline (OR 1.2, P =
0.002), i.e., for a 1-unit increase in CSI, the odds of having
DUs at baseline increased by a factor of 1.19 (Table 2).
In the subgroup of DU-naive patients at baseline,
14% of never smokers developed new DUs between the 2
visits, compared to 16% ex-smokers and 8% current smok-
ers (P = 0.05). Ex-smokers had comparable odds than never
smokers to develop DUs between the 2 visits (OR 1.1, P =
0.7); current smokers developed DUs less often than never
smoking patients (OR 0.5, P = 0.031). The smoking intensity
was not associated with incident DUs during the observa-
tion period (see Supplementary Table 7, available at http://
onlinelibrary.wiley.com/doi/10.1002/art.40557/abstract).
DISCUSSION
Our study is by far the largest to prospectively
investigate the effect of smoking on SSc outcomes. Smok-
ing was common in our patients; however, it was less com-
mon than in Anglo-Saxon cohorts and also much lower
than the European average of ~28% (4,5,13).
The EUSTAR cohort replicated the known adverse
effect of smoking on bronchial airways in terms of a
decline in FEV1/FVC and DLCO. Given the absence of dis-
cernible adverse effects of smoking on systolic PAP, the
effect of smoking on diffusion capacity may reflect emphy-
sema rather than precapillary pulmonary vasculopathy.
Adverse effects of smoking on pulmonary airway obstruc-
tion and diffusing capacity were also seen in 2 cohorts of
137 SSc patients (14) and 19 smokers (15). In accordance
with findings in one of these cohorts (14), but in contrast
to the second study (15), we found no association between
lung compliance (FVC) and smoking status.
This investigation also demonstrated no robust effect
of smoking on DU prevalence and incidence when assessing
the smoking behavior itself or the smoking intensity, which is
similar to the findings in 2 smaller studies (16,17). We even
found a negative association between tobacco exposure and
incident DUs during the follow-up in a subgroup of DU-
naive patients (OR 0.5). This effect could not be explained
by differences in immunosuppressive and vasoactive medica-
tion (data not shown). However, when we assessed smoking
using the CSI, we did find an association of smoking with
DU prevalence, which is similar to the results in another,
although quite smaller, study also using the CSI (4). This dif-
ference could partially arise due to a “healthy smoker
effect,” although this bias has partly been accounted for by
the CSI (18). Given these results, it is difficult to draw robust
conclusions on the effect of smoking onDUs.
In our study, smokers had a lower prevalence of
Scl-70 autoantibodies than previous and never smokers.
This imbalance in autoantibody status is also in accor-
dance with that found in another study, in which Scl-70–
positive patients were more likely to be never smokers
than ever smokers (2), raising the possibility of an
etiopathologic link between smoking and Scl-70 positivity.
The question, however, is whether this imbalance is partly
due to a link, maybe a causal one, between smoking and
autoantibody status, or whether it is partly explained by a
“healthy smoker effect,” especially as the prevalence of
Scl-70 positivity in previous smokers is more comparable
to that in never smokers than in current smokers.
Like all registry-based studies, the EUSTAR
cohort has limitations. We had no means of verifying
the smoking information provided by the patients; how-
ever, we were able to demonstrate known adverse
Table 2. Regression analysis comparing outcomes at baseline and
progression of outcomes according to the CSI*
Outcome
CSI, mean
(range)†
CSI
b‡ 95% CI P
Baseline
FEV1/FVC ratio 0.45 (0–4.09) 2.71 3.46, 1.97 <0.001
FVC 0.34 (0–5.12) 0.41 0.39, 1.22 0.32
Single-breath
DLCO
0.27 (0–2.94) 4.38 5.89, 2.88 <0.001
Systolic PAP 0.23 (0–2.61) 2.08 3.57, 0.58 0.006
MRSS 0.40 (0–7.05) 0.20 0.03, 0.43 0.088
DU current 0.35 (0–7.94) 1.19§ 1.07, 1.32 0.002
Follow-up–
FEV1/FVC ratio 0.33 (0–6.69) 0.45 0.93, 0.02 0.059
FVC 0.46 (0–6.36) 0.32 0.01, 0.66 0.059
Single-breath
DLCO
0.43 (0–4.02) 0.37 0.16, 0.90 0.17
Systolic PAP 0.35 (0–6.19) 0.21 0.76, 0.34 0.45
MRSS 0.43 (0–6.36) 0.16 0.29, 0.02 0.021
New DU
between visits
0.30 (0–8.37) 0.83§ 0.68, 1.00 0.056
* Comprehensive Smoking Index (CSI) scores were adjusted for age, sex,
time since the onset of Raynaud’s phenomenon (RP), time since the first
non-RP manifestation, antibody status, and extent of skin involvement.
95% CI = 95% confidence interval; FEV1/FVC = forced expiratory vol-
ume in 1 second/forced vital capacity; DLCO = diffusing capacity for car-
bon monoxide; PAP = pulmonary artery pressure as estimated by
echocardiography; MRSS =modified Rodnan skin thickness score.
† Illustrates each outcome’s CSI score based on the imputed data set.
Higher CSI scores indicate more smoking; never smokers have a CSI
score of 0.
‡ Beta values represent the additive increase or decrease in the out-
come variable per unit increase in the CSI.
§ Value shown is the odds ratio (OR) for current digital ulcer (DU)
and new DU between visits in the DU-naive population and repre-
sents the increase in odds for the presence of the outcome variable
per unit CSI increase. OR values >1 indicate that increased smoking
increases the likelihood of occurrence of the outcome.
– Assessed the projected change per 12 months of the outcomes.
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effects of smoking on airway obstruction, suggesting
that the information provided by the patients was not
random and that our study was powered to detect
meaningful changes in other parameters.
By requiring the study population to have a follow-
up visit, there is a possibility that we excluded sicker
patients, i.e., that we introduced a selection bias for health-
ier patients. However, at baseline the patients who were
excluded due to the absence of a follow-up visit within the
required time frame exhibited similar clinical characteristics
as the included patients (see Supplementary Table 6, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40557/abstract), which
provides evidence against a major selection bias.
In conclusion, our study demonstrates an adverse
effect of smoking on pulmonary airways, but no effects on
SSc-specific pulmonary and cutaneous involvement. These
data provide evidence against a major role of tobacco-asso-
ciated free radicals and vasoconstrictory and immunomodu-
latory effects in the pathogenesis of SSc vasculopathy and
fibrosis.
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